Study wrapper · #918
Gestational Weight Gain and Pregnancy Outcomes After Semaglutide Exposure.
Editor's note
This propensity-matched retrospective cohort compared pregnancy-exposed users, former users, and non-users using linked medical and pharmacy data. Semaglutide exposure was associated with elevated risks across several pregnancy outcomes, with no significant difference between those who stopped before versus during pregnancy. As an observational study it cannot establish causation, and residual confounding and rebound effects after discontinuation complicate interpretation.
Plain-language abstract
In a large retrospective cohort, semaglutide use before or during pregnancy was associated with higher risks of excessive gestational weight gain, gestational diabetes, excessive fetal growth, and cesarean delivery compared with non-users. Risks were similar whether use stopped before or continued into pregnancy, which the authors suggest points to rebound effects after discontinuation rather than intrauterine exposure.